Rutin, a plant compound (quercetin attached to a sugar), is sold as an oral supplement in the hope of supporting health and longevity. Most human evidence concerns chemically modified relatives used for leg-vein complaints. For rutin itself, a few small trials on blood glucose, blood fats and blood pressure show mixed results; lifespan findings come from animals only. Benefit is plausible but largely unproven; risks are mostly mild. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Hemoglobin A1c | 4.0–5.6% (standard reference range); no rutin-specific target, so track change from own baseline | Marker rutin is expected to change (type 2 diabetes trial) |
| Fasting glucose | 70–99 mg/dL (3.9–5.5 mmol/L) (standard reference range); no rutin-specific target, so track change from own baseline | Marker rutin is expected to change (type 2 diabetes trial) |
| LDL cholesterol, HDL cholesterol and total cholesterol | No established target; track change from own baseline | Markers rutin is expected to change (type 2 diabetes trial) |
| Blood pressure | No established target; track change from own baseline | Marker rutin is expected to change (type 2 diabetes trial); safety check with antihypertensive medicines (theoretical) |
| Immunosuppressant trough level (cyclosporine, tacrolimus) | No established target; track change from own baseline | Safety check (theoretical): lowered cyclosporine exposure in rats |
| INR | 0.8–1.2 in people not taking anticoagulants (standard reference range) | Safety check (theoretical): possible added bleeding tendency |
Cadence: Metabolic markers rechecked at 3 months, then every 6–12 months; medicine levels or clotting tests rechecked within weeks of starting or stopping (common practice)